• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (100)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Psychiatry  • Depression  • Mood Disorders  • Psychopharmacology  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

A Multisite Study From the Consortium for Research in Electroconvulsive Therapy (CORE)

Charles H. Kellner, MD; Rebecca G. Knapp, PhD; Georgios Petrides, MD; Teresa A. Rummans, MD; Mustafa M. Husain, MD; Keith Rasmussen, MD; Martina Mueller, PhD; Hilary J. Bernstein, DHA; Kevin O’Connor, MD; Glenn Smith, PhD; Melanie Biggs, PhD; Samuel H. Bailine, MD; Chitra Malur, MD; Eunsil Yim, MS; Shawn McClintock, MS; Shirlene Sampson, MD; Max Fink, MD

Arch Gen Psychiatry. 2006;63:1337-1344.

Background  Although electroconvulsive therapy (ECT) has been shown to be extremely effective for the acute treatment of major depression, it has never been systematically assessed as a strategy for relapse prevention.

Objective  To evaluate the comparative efficacy of continuation ECT (C-ECT) and the combination of lithium carbonate plus nortriptyline hydrochloride (C-Pharm) in the prevention of depressive relapse.

Design  Multisite, randomized, parallel design, 6-month trial performed from 1997 to 2004.

Setting  Five academic medical centers and their outpatient psychiatry clinics.

Patients  Two hundred one patients with Structured Clinical Interview for DSM-IV–diagnosed unipolar depression who had remitted with a course of bilateral ECT.

Interventions  Random assignment to 2 treatment groups receiving either C-ECT (10 treatments) or C-Pharm for 6 months.

Main Outcome Measure  Relapse of depression, compared between the C-ECT and C-Pharm groups.

Results  In the C-ECT group, 37.1% experienced disease relapse, 46.1% continued to have disease remission at the study end, and 16.8% dropped out of the study. In the C-Pharm group, 31.6% experienced disease relapse, 46.3% continued to have disease remission, and 22.1% dropped out of the study. Both Kaplan-Meier and Cox proportional hazards regression analyses indicated no statistically significant differences in overall survival curves and time to relapse for the groups. Mean ± SD time to relapse for the C-ECT group was 9.1 ± 7.0 weeks compared with 6.7 ± 4.6 weeks for the C-Pharm group (P = .13). Both groups had relapse proportions significantly lower than a historical placebo control from a similarly designed study.

Conclusions  Both C-ECT and C-Pharm were shown to be superior to a historical placebo control, but both had limited efficacy, with more than half of patients either experiencing disease relapse or dropping out of the study. Even more effective strategies for relapse prevention in mood disorders are urgently needed.

Author Affiliations: Department of Psychiatry, University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark (Drs Kellner, Petrides, and O’Connor); Departments of Psychiatry and Behavioral Sciences (Dr Kellner) and Biostatistics, Bioinformatics, and Epidemiology (Drs Knapp and Mueller and Mss Bernstein and Yim), Medical University of South Carolina, Charleston; Department of Psychiatry, The Zucker Hillside Hospital, North Shore–Long Island Health System, Glen Oaks, NY (Drs Petrides, Bailine, Malur, and Fink); Department of Psychiatry and Psychology, Mayo Foundation, Rochester, Minn (Drs Rummans, Rasmussen, Smith, and Sampson); and Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas (Drs Husain and Biggs and Mr McClintock).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Targeting Treatment-Resistant Depression
Mathys and Mitchell
Journal of Pharmacy Practice 2011;24:520-533.
ABSTRACT | FULL TEXT  

Position Statement: Electroconvulsive Therapy
J Am Psychiatr Nurses Assoc 2011;17:207-208.
 

Brain Stimulation Therapies for Mood Disorders: The Continued Necessity of Electroconvulsive Therapy
Nahas and Anderson
J Am Psychiatr Nurses Assoc 2011;17:214-216.
 

Electroconvulsive Therapy: How Effective Is It?
Weiner and Falcone
J Am Psychiatr Nurses Assoc 2011;17:217-218.
 

Combined catecholamine and indoleamine depletion following response to ECT
Cassidy et al.
Br. J. Psychiatry 2010;196:493-494.
ABSTRACT | FULL TEXT  

Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial
Kellner et al.
Br. J. Psychiatry 2010;196:226-234.
ABSTRACT | FULL TEXT  

Effect of Concomitant Pharmacotherapy on Electroconvulsive Therapy Outcomes: Short-term Efficacy and Adverse Effects
Sackeim et al.
Arch Gen Psychiatry 2009;66:729-737.
ABSTRACT | FULL TEXT  

ECT's increasing evidence base and positive profile
Ng
BMJ 2009;338:b390-b390.
FULL TEXT  

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2008;22:343-396.
ABSTRACT  

No difference in depression relapse rates between maintenance electroconvulsive therapy and lithium plus nortriptyline
Freemantle
Evid. Based Ment. Health 2007;10:79-79.
FULL TEXT  

Electroconvulsive Therapy: Evidence and Challenges
Fink and Taylor
JAMA 2007;298:330-332.
FULL TEXT  

ECT as Continuation Therapy
JWatch Psychiatry 2007;2007:2-2.
FULL TEXT